ProCE Banner Activity

Phase II Trial of Ponatinib + Blinatumomab in Adults With Ph+ ALL

Slideset Download
Conference Coverage
The chemotherapy-free combination of ponatinib and blinatumomab has demonstrated high response rates, including deep and durable responses, in patients with newly diagnosed and relapsed/refractory Ph+ ALL.

Released: June 06, 2022

Expiration: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab